# Maria Luisa CaÃ±adas

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 49 papers | 1,523 citations | 361413 20 h-index | 345221 36 g-index |
| 51 all docs | 51 docs citations | 51 times ranked | 2442 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. Blood Cancer Journal, 2022, 12, 79. | 6.2 | 1 |
| 2 | Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis. Molecular Neurobiology, 2021, 58, 4716-4726. | 4.0 | 4 |
| 3 | The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679. | 27.8 | 353 |
| 4 | Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. Surgical Oncology, 2020, 35, 388-398. | 1.6 | 10 |
| 5 | Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease. BMC Medical Genomics, 2020, 13, 120. | 1.5 | 56 |
| 6 | Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis. Pathology Research and Practice, 2020, 216, 152860. | 2.3 | 10 |
| 7 | Genetic Strategies to Understand Human Diabetic Nephropathy: In Silico Strategies for Molecular Dataâ€"Association Studies. Methods in Molecular Biology, 2020, 2067, 241-275. | 0.9 | 0 |
| 8 | The Challenges of Chromosome Y Analysis and the Implications for Chronic Kidney Disease. Frontiers in Genetics, 2019, 10, 781. | 2.3 | 14 |
| 9 | Genetic Susceptibility to Chronic Kidney Disease â€“ Some More Pieces for the Heritability Puzzle. Frontiers in Genetics, 2019, 10, 453. | 2.3 | 74 |
| 10 | Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients. Mutation Research - Reviews in Mutation Research, 2019, 781, 63-70. | 5.5 | 10 |
| 11 | Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis. BMJ Open, 2019, 9, e026777. | 1.9 | 42 |
| 12 | Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Gastroenterology, 2019, 156, 43-45. | 1.3 | 15 |
| 13 | Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491. | 4.7 | 23 |
| 14 | Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease. Journal of Proteomics, 2019, 193, 93-122. | 2.4 | 37 |
| 15 | Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics Journal, 2019, 19, 164-177. | 2.0 | 28 |
| 16 | Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer. Pathology Research and Practice, 2018, 214, 44-52. | 2.3 | 12 |
| 17 | Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 167-172. | 2.0 | 31 |
| 18 | Pharmacogenetic biomarkers of response in Crohnâ€™s disease. Pharmacogenomics Journal, 2018, 18, 1-13. | 2.0 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Genomic approaches in the search for molecular biomarkers in chronic kidney disease. Journal of Translational Medicine, 2018, 16, 292. | 4.4 | 31 |
| 20 | Diabetes-Related Neurological Implications and Pharmacogenomics. Current Pharmaceutical Design, 2018, 24, 1695-1710. | 1.9 | 34 |
| 21 | Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutation Research - Reviews in Mutation Research, 2017, 771, 32-58. | 5.5 | 30 |
| 22 | ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis. Surgical Oncology, 2017, 26, 473-482. | 1.6 | 14 |
| 23 | Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. Surgical Oncology, 2017, 26, 278-285. | 1.6 | 20 |
| 24 | Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer. Pharmacogenetics and Genomics, 2017, 27, 438-444. | 1.5 | 9 |
| 25 | Liquid biopsy in early stage lung cancer. Translational Lung Cancer Research, 2016, 5, 517-524. | 2.8 | 28 |
| 26 | Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas. Head and Neck, 2016, 38, 1772-1779. | 2.0 | 5 |
| 27 | ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients. Pharmacological Research, 2016, 108, 111-118. | 7.1 | 12 |
| 28 | Gene polymorphisms as predictors of response to biological therapies in psoriasis patients. Pharmacological Research, 2016, 113, 71-80. | 7.1 | 19 |
| 29 | Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients. Pharmacological Research, 2016, 111, 877-884. | 7.1 | 29 |
| 30 | Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacological Research, 2016, 111, 264-271. | 7.1 | 35 |
| 31 | Molecular biomarkers in colorectal carcinoma. Pharmacogenomics, 2015, 16, 1189-1222. | 1.3 | 14 |
| 32 | Extrapolation of acenocoumarol pharmacogenetic algorithms. Vascular Pharmacology, 2015, 74, 151-157. | 2.1 | 5 |
| 33 | MET: a new promising biomarker in non-small-cell lung carcinoma. Pharmacogenomics, 2015, 16, 631-647. | 1.3 | 21 |
| 34 | Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer. Breast Cancer Research and Treatment, 2015, 153, 493-505. | 2.5 | 21 |
| 35 | MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. Pharmacological Research, 2015, 102, 90-106. | 7.1 | 4 |
| 36 | De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer. Pharmacogenomics, 2015, 16, 1411-1426. | 1.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics, 2015, 16, 1843-1862. | 1.3 | 180 |
| 38 | Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenetics and Genomics, 2014, 24, 501-513. | 1.5 | 10 |
| 39 | Novel BRAFI599Ins Mutation Identified in a Follicular Variant of Papillary Thyroid Carcinoma: A Molecular Modeling Approach. Endocrine Practice, 2014, 20, e75-e79. | 2.1 | 4 |
| 40 | Pharmacogenetics role in the safety of acenocoumarol therapy. Thrombosis and Haemostasis, 2014, 112, 522-536. | 3.4 | 20 |
| 41 | Could 18F-FDG-PET/CT avoid unnecessary thyroidectomies in patients with cytological diagnosis of follicular neoplasm?. Langenbeck's Archives of Surgery, 2013, 398, 709-716. | 1.9 | 19 |
| 42 | Pharmacogenetics and Pharmacogenomics of Chronic Kidney Disease Comorbidities and Kidney Transplantation. , 2013, , 801-817. | | 2 |
| 43 | Pharmacogenetics of Oral Anticoagulants. , 2013, , 435-467. | | 0 |
| 44 | Pharmacogenomics and Gut Microbiota Biomarkers in Obesity. , 2013, , 575-601. | | 0 |
| 45 | Pharmacogenetics of Osteoporosis: Towards Novel Theranostics for Personalized Medicine?. OMICS A Journal of Integrative Biology, 2012, 16, 638-651. | 2.0 | 9 |
| 46 | Reduction of False-Negative Papillary Thyroid Carcinomas by the Routine Analysis of BRAFT1799A Mutation on Fine-Needle Aspiration Biopsy Specimens. Annals of Surgery, 2012, 255, 986-992. | 4.2 | 39 |
| 47 | Pharmacogenetic Polymorphisms Contributing to Toxicity Induced by Methotrexate in the Southern Spanish Population with Rheumatoid Arthritis. OMICS A Journal of Integrative Biology, 2012, 16, 589-595. | 2.0 | 46 |
| 48 | BRAFT1799A mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. EndocrinologÃa Y NutriciÃ³n (English Edition), 2011, 58, 175-184. | 0.5 | 11 |
| 49 | Apoptosis and necrosis in human ejaculated spermatozoa. Human Reproduction, 2004, 19, 607-610. | 0.9 | 102 |